Business Process Reengineering ( BPR ) BPR atau Reengineering ...
Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat...
Transcript of Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat...
![Page 1: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/1.jpg)
Reengineering Vancomycin to Combat Bacterial Resistance
Matthew Giletto September 18, 2013
CEM 958
![Page 2: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/2.jpg)
Overview
• Why bacterial resistance to antibiotics is an important area of research
• Review the history of vancomycin, its structural elucidation and mechanism of action
• Track the development of bacterial resistance to vancomycin
• Examine SAR work on vancomycin • Learn how vancomycin has been assembled in
the laboratory and propose how this knowledge may let us build ‘better’ vancomycin(s)
![Page 3: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/3.jpg)
Bacterial resistance to antibiotics
• Meticillin resistant Staphylococcus aureus,‘MRSA’, – killed 19,000 people (2005)
– invasively effected 94,000 in the US (2005)
– 3-4 billion dollars (2005)
• Vancomycin was ‘last line’ defense against multidrug resistant pathogens
• Vancomycin resistant S. aureus, ‘VRSA’
• Vancomycin resistant Enterococci, ‘VRE’
• Resistance is acquired as a result of gene transfer from nonpathogens to pathogens and between pathogens
Walsh, C. T.; Fischbach M. A. Sci. Am., 2009, 301, 44. Klevens, R. M. et al. J. Am. Med. Assoc., 2007; 298, 1763.
Wengel, L. et. al. Science; 2003; 302 , 1569. Neu, H.C. Science, 1992, 257, 1064.
Leclercq, R. et. al. N. Eng. J. Med., 1988, 319, 157.
![Page 4: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/4.jpg)
Solution
• To use organic synthesis (total synthesis, semi-synthesis and catalysis) as a tool to solve problems in diverse areas of science (chemistry, biology, medicine) that are not solvable with other methods
![Page 5: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/5.jpg)
Classes of antibiotics active against Gram Positive pathogens
![Page 6: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/6.jpg)
X-ray Structure of CDP-I
Bardsley, B., Williams, D. H.; Angew. Chemie. Int. Ed.; 1999; 38; 1172. Williams, D. H.; Williamson, M. P.; J. Am. Chem. Soc.; 1981; 103; 6580.
Harris, C. M.; Harris, T. M.; J. Am. Chem. Soc.; 1982; 104; 4293. Williams, D. H. et. al.; Nature; 1978; 271; 223.
Marshall, F. J.; J. Med. Chem.; 1965; 8; 18.
![Page 7: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/7.jpg)
Rearrangement to CDP-I
Boger, D. L. et. al. J. Am. Chem. Soc., 1998, 120, 8920. Harris, C. M.; Harris, T. M. J. Am. Chem. Soc., 1982, 104, 4293.
![Page 8: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/8.jpg)
Key nOe’s of CDP-I and vancomycin
Nitanai, Y. et. al. J. Mol. Biol., 2009, 385, 1422. Loll, P. J. J. Am. Chem. Soc., 1997, 119, 1516.
Williams, D. H.; Williamson, M. P.. J. Am. Chem. Soc., 1981, 103, 6580.
![Page 9: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/9.jpg)
Vancomycin inhibits cell wall synthesis at transglycosylation
• Schaefer: D-[1-13C]-ala incorporation exclusive to cell wall precursors AND quantitatively detectable in solid state NMR
• % D- [1-13C]-ala-D-[1-13C]-ala in growing Enterococci is 24
• % D- [1-13C]-ala-D-[1-13C]-ala 45 min after 25 mg/mL vancomycin doubles to 48 – Diagnostic of accumulation of cell wall precursors in cytoplasm
Schaefer, J. et. al. Biochemistry, 2013, 52, 3405. Schaefer, J. et. al. J. Mol. Biol., 2009, 392, 1178. Schaefer, J. et. al. J. Mol. Biol., 2006, 357, 1253.
Kricheldorf, H. R.; Muller, D. Macromolecules, 1983, 16, 615.
![Page 10: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/10.jpg)
Bacterial cell wall synthesis: Phase 1
Schaefer, J. et. al. Biochemistry, 2013, 52, 3405. Schaefer, J. et. al. J. Mol. Biol., 2009, 392, 1253.
Kahne, D. et. al. Chem. Rev., 2005, 105, 425.
![Page 11: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/11.jpg)
Installation of D-asp bridge in Enterococci
Bellias, S. et. al. J. Biol. Chem., 2006, 281, 11586.
![Page 12: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/12.jpg)
Phase 2
Kahne, D. et. al. Chem. Rev., 2005, 105, 425.
![Page 13: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/13.jpg)
Kahne, D. et. al. Chem. Rev., 2005, 105, 425.
![Page 14: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/14.jpg)
Phase III Step 1:transglycosylation
Kahne, D. et. al. Chem. Rev., 2005, 105, 425.
![Page 15: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/15.jpg)
Binding model in susceptible bacteria
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
Williams, D. H.; Bardsley, B. Angew. Chemie. Int. Ed., 1999, 38, 1172. Williams, D. H. et. al. J. Am. Chem. Soc., 1983, 105, 1332.
Perkins, H.R.; Nieto, M. Biochem. J., 1971, 123, 789.
![Page 16: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/16.jpg)
Binding model in resistant bacteria
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
Williams, D. H.; Bardsley, B. Angew. Chemie. Int. Ed., 1999, 38, 1172. Williams, D. H. et. al. J. Am. Chem. Soc., 1983, 105, 1332.
Perkins, H.R.; Nieto, M. Biochem. J., 1971, 123, 789.
![Page 17: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/17.jpg)
Potential dual binding capacity of amidines
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284. Boger, D. L.; Crowley, B. M. J. Am. Chem. Soc., 2006, 128, 2885.
![Page 18: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/18.jpg)
Activating the mechanism of resistance
Wright G. D. et. al. Nature Chemical Biology , 2010, 6, 327.
![Page 19: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/19.jpg)
Probing the SAR for possible solutions to bacterial resistance
![Page 20: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/20.jpg)
Des-leucyl vancomycin series
Kahne, D. et. al. Chem. Rev., 2005, 105, 425. Kahne, D. et. al.; Science, 1999; 284, 507.
Williams, D H. et. al J. Antibiot., 1995, 48, 805.
![Page 21: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/21.jpg)
Des-leucyl vancomycin series
Kahne, D. et. al. Chem. Rev., 2005, 105, 425. Kahne, D. et. al.; Science, 1999; 284, 507.
Williams, D H. et. al J. Antibiot., 1995, 48, 805.
![Page 22: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/22.jpg)
Des-leucyl chlorobiphenyl vancomycin series
Schaefer, J. et. al. J. Mol. Biol., 2009, 392, 1253.
Kahne, D. et. al. Chem. Rev., 2005, 105, 425. Kahne, D. et. al. Science, 1999, 284, 507.
![Page 23: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/23.jpg)
Des-leucyl chlorobiphenyl vancomycin series
Schaefer, J. et. al. J. Mol. Biol., 2009, 392, 1253.
Kahne, D. et. al. Chem. Rev., 2005, 105, 425. Kahne, D. et. al. Science, 1999, 284, 507.
“The complexity of the peptide portion of vancomycin makes it virtually impossible to reengineer the peptide backbone to include new contacts to the modified substrate.” D. Kahne
![Page 24: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/24.jpg)
Oritavancin
Zhanel, G. G. et. al. Drugs, 2010, 70, 859. Schaefer, J. Biochemistry, 2008, 47, 10155. Allen, N. et. al. J. Antibiot., 1997, 50, 677.
![Page 25: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/25.jpg)
Oritavancin inhibits transpeptidation
Schaefer, J. et. al. J. Mol. Biol., 2009, 392, 1253.
![Page 26: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/26.jpg)
Site-Selective bromination of vancomycin
Miller, S.J.; Pathak, T.P. J. Am. Chem. Soc., 2012, 134, 6120.
![Page 27: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/27.jpg)
Proposed Binding Model
Miller, S.J.; Pathak, T.P. J. Am. Chem. Soc., 2012, 134, 6120.
![Page 28: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/28.jpg)
Modifications external to binding site
• Modifying carbohydrate = new mechanism
• Catalysis
Schaefer, J. et. al. Biochemistry, 2013, 52, 3405. Miller, S.J.; Pathak, T.P. J. Am. Chem. Soc., 2012, 134, 6120.
Schaefer, J. et. al. J. Mol. Biol., 2009, 392, 1253.
![Page 29: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/29.jpg)
Redesigning vancomycin • Total syntheses: Nicolaou, Evans, Boger
Nicolaou, K. C. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2708. Evans, D. A. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2700.
Boger, D. L. et. al. J. Am. Chem. Soc., 1999, 121, 3226. Smith, G. G. et. al. J. Org. Chem., 1983, 48, 5368.
![Page 30: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/30.jpg)
Retrosynthetic analysis
Kahne, D. et. al. J. Am. Chem. Soc., 1998, 120, 11014. Nicolaou, K. C. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2708.
Evans, D. A. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2700. Boger, D. L. et. al. J. Am. Chem. Soc., 1999, 121, 3226.
![Page 31: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/31.jpg)
Retrosynthesis of Eastern Hemisphere
Nicolaou, K. C. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2708.
Evans, D. A. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2700. Boger, D. L. et. al. J. Am. Chem. Soc., 1999, 121, 3226.
![Page 32: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/32.jpg)
Retrosynthesis of Western Hemisphere
Nicolaou, K. C. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2708. Evans, D. A. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2700.
Boger, D. L. et. al. J. Am. Chem. Soc., 1999, 121, 3226.
![Page 33: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/33.jpg)
The Nicolaou retrosynthetic approach
Nicolaou, K. C. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2708.
![Page 34: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/34.jpg)
Synthesizing the AB ring atropisomer
Nicolaou, K. C. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2708.
![Page 35: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/35.jpg)
Synthesizing the CD macrocycle
Nicolaou, K. C. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2708.
![Page 36: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/36.jpg)
Synthesizing the DE macrocycle
Nicolaou, K. C. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2708.
![Page 37: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/37.jpg)
Learning from the Nicolaou approach
Nicolaou, K. C. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2708.
![Page 38: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/38.jpg)
Evans’ Retro of the Western Hemisphere
Evans, D. A. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2700.
![Page 39: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/39.jpg)
Synthesizing of AB macrocycle
Evans, D. A. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2700.
![Page 40: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/40.jpg)
Synthesizing the CD macrocycle
Evans, D. A. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2700.
![Page 41: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/41.jpg)
Preparing for the AB ring equilibration
Evans, D. A. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2700.
![Page 42: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/42.jpg)
Equilibrating the AB macrocycle
Evans, D. A. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2700.
Evans, D. A. J. Am. Chem. Soc., 1993, 115, 6426.
![Page 43: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/43.jpg)
Synthesizing the DE macrocycle
Evans, D. A. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2700.
![Page 44: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/44.jpg)
Evans’ synthesis
Evans, D. A. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2700.
![Page 45: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/45.jpg)
Nicolaou versus Evans
Nicolaou, K. C. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2708. Evans, D. A. et. al. Angew. Chemie. Int. Ed., 1998, 37, 2700.
![Page 46: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/46.jpg)
The Boger strategy: Equilibration
Boger, D. L. et. al. J. Am. Chem. Soc., 1998, 120, 8920.
![Page 47: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/47.jpg)
The Boger synthesis of vancomycin amidine aglycon
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
![Page 48: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/48.jpg)
Incorporating the A ring
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
![Page 49: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/49.jpg)
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
![Page 50: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/50.jpg)
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
![Page 51: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/51.jpg)
Completion
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
![Page 52: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/52.jpg)
Vancomycin aglycon vs vancomycin amidine aglycon
Boger, D. L.. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
![Page 53: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/53.jpg)
Dual binding capacity of amidines
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
![Page 54: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/54.jpg)
Analogs and factors influencing binding
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284. Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 8790.
![Page 55: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/55.jpg)
An optimized analog: Amidine Oritavancin
![Page 56: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/56.jpg)
Proposed traditional route
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
![Page 57: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/57.jpg)
Amidine Oritavancin
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284. Nicolaou, K. C. et. al. Chem. Eur. J., 1999, 5, 2648.
![Page 58: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/58.jpg)
Amidine Oritavancin
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284. Nicolaou, K. C. et. al. Chem. Eur. J., 1999, 5, 2648.
![Page 59: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/59.jpg)
Boger, D. L. et. al. J. Am. Chem. Soc.; 2012; 134, 1284. Nicolaou, K. C. et. al. Chem. Eur. J., 1999, 5, 2648.
![Page 60: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/60.jpg)
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284. Nicolaou, K. C. et. al. Chem. Eur. J., 1999, 5, 2648.
![Page 61: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/61.jpg)
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
Nicolaou, K. C. et. al. Chem. Eur. J., 1999, 5, 2648.
![Page 62: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/62.jpg)
Amidine Oritavancin
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
Nicolaou, K. C. et. al. Chem. Eur. J., 1999, 5, 2648.
![Page 63: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/63.jpg)
Amidine Oritavancin
![Page 64: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/64.jpg)
Proposed peptide catalytic route to Amidine Oritavancin
Boger, D. L. et. al. J. Am. Chem. Soc., 2012, 134, 1284.
![Page 65: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/65.jpg)
Miller and Ley
Miller, S.J.; Pathak, T.P. J. Am. Chem. Soc., 2012, 134, 6120. Ley, S. V. et. al. J. Chem. Soc. Perkin Trans. I, 2001, 358.
![Page 66: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/66.jpg)
A combined approach
Miller, S.J.; Pathak, T.P. J. Am. Chem. Soc., 2012, 134, 6120. Ley, S. V. et. al. J. Chem. Soc. Perkin Trans. I, 2001, 358.
![Page 67: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/67.jpg)
A peptidomimetic Lawessons reagent
Miller, S.J.; Pathak, T.P. J. Am. Chem. Soc., 2012, 134, 6120. Joullie, M. et. al. J. Am. Chem. Soc.; 2002; 124; 520.
Ley, S. V. et. al. J. Chem. Soc. Perkin Trans. I, 2001, 358.
![Page 68: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/68.jpg)
Putative binding model
Miller, S.J.; Pathak, T.P. J. Am. Chem. Soc., 2012, 134, 6120. Ley, S. V. et. al. J. Chem. Soc. Perkin Trans. I, 2001, 358.
![Page 69: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/69.jpg)
Conclusions
• Important scientific problems can be better understood and solved with the tools of organic synthesis
• Specifically the problem of inevitable evolution of bacterial resistance to antibiotics can be countered in ways that only organic synthesis could accomplish, restoring our ability to combat deadly and otherwise untreatable diseases
![Page 70: Reengineering Vancomycin to Combat Bacterial Resistance · Reengineering Vancomycin to Combat Bacterial Resistance Matthew Giletto September 18, 2013 CEM 958](https://reader030.fdocuments.net/reader030/viewer/2022040810/5e501dd6dacd2c44a50f8da0/html5/thumbnails/70.jpg)
Thanks
• Dr. Tepe and current group members
– Nicole Hewlett
– Travis Bethel
– Greg Patten
– Jacob Ludwig
• Dr. Huang
• The audience
• Support of Holeigh, friends, and family